[go: up one dir, main page]

WO2018192590A3 - Composition pharmaceutique orale stable et procédé de préparation associé - Google Patents

Composition pharmaceutique orale stable et procédé de préparation associé Download PDF

Info

Publication number
WO2018192590A3
WO2018192590A3 PCT/CN2018/091940 CN2018091940W WO2018192590A3 WO 2018192590 A3 WO2018192590 A3 WO 2018192590A3 CN 2018091940 W CN2018091940 W CN 2018091940W WO 2018192590 A3 WO2018192590 A3 WO 2018192590A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical composition
pharmaceutically acceptable
method therefor
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/091940
Other languages
English (en)
Chinese (zh)
Other versions
WO2018192590A2 (fr
Inventor
高慧燕
张利锋
陈见阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Jingxin Pharmaceutical Co Ltd
Original Assignee
Zhejiang Jingxin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Jingxin Pharmaceutical Co Ltd filed Critical Zhejiang Jingxin Pharmaceutical Co Ltd
Publication of WO2018192590A2 publication Critical patent/WO2018192590A2/fr
Publication of WO2018192590A3 publication Critical patent/WO2018192590A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale stable et un procédé de préparation associé. La composition contient une quantité efficace d'un composé ayant la structure représentée par la formule I ou un sel pharmaceutiquement acceptable de celui-ci et un support pharmaceutiquement acceptable, le support pharmaceutiquement acceptable comprenant un polymère ayant un point de fusion, une température de transition vitreuse et une température de ramollissement inférieure à 180 °C, le rapport en masse du polymère relativement au composé ayant la structure représentée par la formule I ou son sel pharmaceutiquement acceptable étant supérieur à 1.
PCT/CN2018/091940 2017-04-21 2018-06-20 Composition pharmaceutique orale stable et procédé de préparation associé Ceased WO2018192590A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710264635.6A CN107007559B (zh) 2017-04-21 2017-04-21 一种稳定的口服药物组合物及其制备方法
CN201710264635.6 2017-04-21

Publications (2)

Publication Number Publication Date
WO2018192590A2 WO2018192590A2 (fr) 2018-10-25
WO2018192590A3 true WO2018192590A3 (fr) 2018-12-20

Family

ID=59446978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/091940 Ceased WO2018192590A2 (fr) 2017-04-21 2018-06-20 Composition pharmaceutique orale stable et procédé de préparation associé

Country Status (2)

Country Link
CN (1) CN107007559B (fr)
WO (1) WO2018192590A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
CN1178662C (zh) * 1995-03-24 2004-12-08 伊莱利利公司 2-甲基-噻吩并-苯并二氮杂�口服制剂
CN101189001A (zh) * 2005-02-15 2008-05-28 伊兰制药国际有限公司 纳米微粒苯并二氮杂䓬气雾剂及注射剂
CN101827597A (zh) * 2007-08-20 2010-09-08 伊沃泰克神经科学有限责任公司 睡眠障碍的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372040C (fr) * 1999-05-12 2008-12-02 Francois Jenck Derive d'imidazodiazepine
US20090054412A1 (en) * 2007-08-20 2009-02-26 John Alan Kemp Treatment of Sleep Disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178662C (zh) * 1995-03-24 2004-12-08 伊莱利利公司 2-甲基-噻吩并-苯并二氮杂�口服制剂
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
CN101189001A (zh) * 2005-02-15 2008-05-28 伊兰制药国际有限公司 纳米微粒苯并二氮杂䓬气雾剂及注射剂
CN101827597A (zh) * 2007-08-20 2010-09-08 伊沃泰克神经科学有限责任公司 睡眠障碍的治疗

Also Published As

Publication number Publication date
WO2018192590A2 (fr) 2018-10-25
CN107007559B (zh) 2020-05-15
CN107007559A (zh) 2017-08-04

Similar Documents

Publication Publication Date Title
EP4512399A3 (fr) Formes à l'état solide de tafamidis et leurs sels
WO2014209841A3 (fr) Composés pour le traitement d'une amyotrophie spinale
WO2012021715A3 (fr) Formulations stables de linaclotide
BR112013025519A2 (pt) composição farmacêutica
WO2019043634A3 (fr) Di-nucléotides cycliques en tant que stimulateurs de modulateurs de gènes d'interféron
HK1248069A1 (zh) 去乙酰氧基微管溶素h及其类似物
WO2018192910A3 (fr) Procédé de fabrication d'une composition de revêtement anti-salissure et revêtement qui en est constitué
WO2017015433A3 (fr) Composé ciblant le facteur d'activation d'il-23 et des lymphocytes b (baff) et utilisations associées
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
HK1217295A1 (zh) 4'-疊氮基，3'-脫氧基-3'-氟取代的核苷衍生物
EP4295916A3 (fr) Sels de 4-amino-n- (1-((3-chloro-2-fluorophényl) amino)-6-méthylisoquinoline-5-yl) thiéno [3,2-d] pyrimidine-7-carboxamide et leurs formes cristallines
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
IL280376A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EP3792253A4 (fr) Composé ayant une nouvelle structure, complexe le comprenant, composition pharmaceutique anticancéreuse et médicament anticancéreux
WO2012108631A3 (fr) Compositions pharmaceutiques comprenant des nanoparticules qui contiennent du révaprazan et procédés de préparation associés
WO2015002755A3 (fr) Composés pour le traitement du paludisme
WO2012029074A3 (fr) Compositions pharmaceutiques de linézolide
EP2497464A3 (fr) Composition pharmaceutique de l'imatinibe methanesulphonate et son procédé de fabrication
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
WO2016137862A3 (fr) Compositions de résistance au cheminement électrique, articles formés à partir de ces dernières et leurs procédés de production
WO2018192590A3 (fr) Composition pharmaceutique orale stable et procédé de préparation associé
WO2011112793A3 (fr) Compositions non aqueuses structurées
EP4251579A4 (fr) Compositions de verre à coefficient de poisson élevé

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18787390

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18787390

Country of ref document: EP

Kind code of ref document: A2